Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: A prospective study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 6, 2012, Pages 1106-1111

  Kee, Kwong Ming ^a   Wang, Jing Houng ^a   Hung, Chao Hung ^a   Chen, Chien Hung ^a   Lee, Chuang Mo ^a   Chang, Kuo Chin ^a   Tseng, Po Lin ^a   Yen, Yi Hao ^a   Lin, Chih Yun ^a   Lu, Sheng Nan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Anti hepatitis C virus antibody titer; Hepatitis C; Interferon therapy; Recombinant immunoblot assay; Sustained virological response

Indexed keywords

HEPATITIS C ANTIBODY; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; THROMBOCYTE COUNT; TREATMENT RESPONSE;

EID: 84861473761     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06946.x     Document Type: Article

References (34)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
2. Formann E, Steindl-Munda P, Hofer H etal. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment. Pharmacol. Ther. 2006; 23: 507-11.
3. Veldt BJ, Saracco G, Boyer N etal. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504-8.
4. Bruno S, Stroffolini T, Colombo M etal. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
5. Yu ML, Lin SM, Chuang WL etal. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir. Ther. 2006; 11: 985-94.
6. Hung CH, Lee CM, Lu SN etal. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J. Viral Hepat. 2006; 13: 409-14.
7. Huang JF, Yu ML, Lee CM etal. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386-patient study from Taiwan. Aliment. Pharmacol. Ther. 2007; 25: 1029-37.
8. Giuberti T, Marin MG, Ferrari C etal. Hepatitis C virus viremia following clinical resolution of acute hepatitis C. J. Hepatol. 1994; 20: 666-71.
9. Wiegand J, Jackel E, Cornberg M etal. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40: 98-107.
10. Lu SN, Tung HD, Chen TM etal. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion? J. Viral Hepat. 2004; 11: 563-70.
11. Hung CH, Lu SN, Wang JH etal. Identified cases of acute hepatitis C from computerized laboratory database: a hospital-based epidemiological and clinical study. J. Infect. 2008; 56: 274-80.
12. Sugiyasu Y, Yuki N, Nagaoka T etal. Histological improvement of chronic liver disease after spontaneous serum hepatitis C virus clearance. J. Med. Virol. 2003; 69: 41-9.
13. Huang JF, Lu SN, Chue PY etal. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. Epidemiol. Infect. 2001; 127: 485-92.
14. Lee PL, Wang JH, Tung HD, Lee CM, Lu SN. A higher than expected recovery rate from hepatitis C infection amongst adolescents: a community study in a hepatitis C-endemic township in Taiwan. Trans. R. Soc. Trop. Med. Hyg. 2004; 98: 367-72.
15. Lu SN, Chen HC, Tang CM etal. Prevalence and manifestations of hepatitis C seropositivity in children in an endemic area. Pediatr. Infect. Dis. J. 1998; 17: 142-5.
16. Lefrere JJ, Girot R, Lefrere F etal. Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion. Transfusion 2004; 44: 343-8.
17. Lefrere JJ, Guiramand S, Lefrere F etal. Full or partial seroreversion in patients infected by hepatitis C virus. J. Infect. Dis. 1997; 175: 316-22.
18. Maylin S, Martinot-Peignoux M, Ripault MP etal. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int. 2009; 29: 511-17.
19. Toyoda H, Kumada T, Kiriyama S etal. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy. Clin. Infect. Dis. 2005; 40: e49-54.
20. Tung HD, Lu SN, Lee CM etal. Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay. J. Viral Hepat. 2002; 9: 304-8.
21. Marinho RT, Pinto RM, Santos ML, de Moura MC. Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus. Liver Int. 2004; 24: 413-18.
22. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol. Methods Res. 2001; 29: 374-93.
23. Huang WS, Lu SN, Wang JH etal. Prediction of viremia for cases of hepatitis C virus (HCV) infection using a third-generation anti-HCV enzyme immunoassay test. Hepatogastroenterology 2005; 52: 893-6.
24. Dai CY, Ho CK, Huang JF etal. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J. Hepatol. 2010; 52: 160-6.
25. Wang CS, Yao WJ, Wang ST, Chang TT, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin. Infect. Dis. 2004; 39: 790-6.
26. Lu SN, Wang JH, Liu SL etal. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006; 107: 2212-22.
27. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
28. Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J. Clin. Gastroenterol. 2009; 43: 758-64.
29. Lee CM, Hung CH, Lu SN, Changchien CS. Hepatitis C virus genotypes: clinical relevance and therapeutic implications. Chang Gung Med. J. 2008; 31: 16-25.
30. Nikolaeva LI, Blokhina NP, Tsurikova NN etal. Virus-specific antibody titres in different phases of hepatitis C virus infection. J. Viral Hepat. 2002; 9: 429-37.
31. Beld M, Penning M, van Putten M etal. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. Hepatology 1999; 29: 1288-98.
32. Martinot-Peignoux M, Marcellin P, Xu LZ etal. Reactivity to c33c antigen as a marker of hepatitis C virus multiplication. J. Infect. Dis. 1992; 165: 595-6.
33. Bassett SE, Brasky KM, Lanford RE. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J. Virol. 1998; 72: 2589-99.
34. Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment. Pharmacol. Ther. 2010; 31: 502-8.